Resources

Our Dedication to Supporting Your Peace of Mind

We know you may have a lot of questions or concerns before having surgery or starting chemotherapy treatment. That’s why we’re dedicated to helping you have peace of mind by connecting you to the latest information about your unique healthcare concerns and treatment options.

Research

MAGOPSA’s current research efforts are conducted in collaboration with the National Cancer Institute (opens new window), the Gynecologic Oncology Group Foundation (GOG) (opens new window) and various industry sponsored protocols.

[photo]

Our research protocols allow us to offer you the opportunity to participate in cutting-edge research. This includes first line treatment for those patients newly diagnosed with gynecologic malignancies, as well as trials for those diagnosed with recurrent or progressive disease. Currently available clinical trials are geared towards ovarian, endometrial and cervical carcinomas.

Each protocol offers patients standard of care treatment along with investigational products that have shown promise in the treatment of cancer. PARP inhibitors, HER2 pathway blockers, anti-VEGF and investigational chemotherapies are being utilized.
A Phase I vaccine trial in advanced epithelial and ovarian cancer is also being launched.
Tissue acquisition at the time of a patient’s initial surgery is another area of research that may offer benefit to the patient by offering specific treatment tailored to the genetic typing of the tumor. This tissue can be sent for chemotherapy sensitivity and/or molecular profiling in an effort to help individualize therapy.

Current Research Protocols

Indication	Stage	Study Name	Study Title
Recurrent Ovarian	I-IV	Yondelis	A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recurrent Ovarian with low CA 125	I-IV	Morab 011	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
Persistent or recurrent Ovarian	I-IV	NRG - 003	Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Persistent or recurrent Cervical	I-IV	NRG - 002	A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Newly diagnosed Ovarian	III-IV	Parp Inhibitor	A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Leiomyoscarcoma	I-IV	LMS	A PHASE III RANDOMIZED TRIAL OF GEMCITABINE PLUS DOCETAXEL FOLLOWED BY DOXORUBICIN VERSUS OBSERVATION FOR UTERUS-LIMITED, HIGH-GRADE UTERINE LEIOMYOSARCOMA
All	I-IV	Caris	A registry of the Target Now test results (biomarker expressions patterns) for evaluation of correlation with clinical outcomes for cancer patients.
All	I-IV	TDAN	Tissue and Data Acquisition for the study of gynecologic disease

Surgical Options

We deliver minimally invasive surgery using da Vinci surgical systems (opens new window).

Learn More (opens new window)

Chemotherapy

Our strong working relationship with the team at Inova’s Schar Cancer Institute brings the highest level of chemotherapy treatment and resources to our patients. Check out the links below for trusted online sources of educational information.